Model 1 β (95% CI) | Model 2 β (95% CI) | Model 3 β (95% CI) | Model 4 β (95% CI) | |
---|---|---|---|---|
Demographics | ||||
Age in years | 0.0 (-0.0–0.1) | 0.1 (-0.0–0.1) | -0.0 (-0.1–0.0) | -0.0 (-0.1–0.0) |
Female gender | 1.2 (-0.1–2.4) | 1.2 (-0.1–2.4) | 0.7 (-0.6–1.9) | 0.7 (-0.6–2.1) |
Patients vs controls | -6.4 (-8.4–-4.3) ** | -4.9 (-7.4–-2.4)* | - | |
Vaccine type | ||||
BNT162b2 x 2 | - | |||
COVID-19 infection and vaccine | 8.3 (-0.2–16.8) | |||
Mixeda | 2.8 (0.2–5.4)* | |||
mRNA-1273 x 2 | 4.4 (3.0–5.9) ** | |||
Medication | ||||
Methotrexate monotherapy | -1.9 (-4.3– 0.5) | - | ||
Interleukin inhibitors | -0.9 (-4.5–2.7) | 1.8 (-1.7–5.3) | ||
Vedolizumab | 0.7 (-3.3–4.7) | 5.1 (0.7–9.5)* | ||
TNF mono | -8.6 (-10.7–-6.5) ** | -6.2 (-8.4–-4.1)** | ||
TNF comb | -8.1 (-10.4–-5.9)** | -6.0 (-8.0–-4.0)** | ||
Rituximab | -0.3 (-4.8–4.2) | 1.0 (-3.3–5.3) | ||
Diagnosis | ||||
Rheumatoid arthritis | - | |||
Psoriatic arthritis | 0.5 (-1.4–2.5) | |||
Spondyloarthritis | 0.8 (-1.4–3.1) | |||
Ulcerative colitis | -2.9 (-5.7–-0.2)* | |||
Crohn’s disease | -2.3 (-4.7–0.1) | |||
R2adjusted | 0.21 | 0.23 | 0.26 | 0.26 |